|
|
Article: Prescribing Options for Treating Inflammation Positioned to Benefit from an Active Drug Pipeline.
- Article from:
- Biotech Week
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Chronic inflammation is a medical condition that is refractory in nature, one that increases in prevalence and incidence with the aging of a given population. The global value of drugs indicated for treating inflammation accounted for more than $15 billion in 2008. Because of favorable demographics, this market is considered to be highly attractive and recently became more competitive with the FDA approvals of two more TNF antagonists - Centocor's Simponi in April and UCB's Cimzia in May. With more than a dozen additional drug candidates targeting inflammation in the development pipeline, this segment will become increasingly crowded, providing caregivers and patients ...